Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. Alternative anticoagulation in atrial fibrillation

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 2, 2014, Pages 199-207

  Pink, J ^a   Pirmohamed, M ^b   Lane, S ^b   Hughes, D A ^a  

^a BANGOR UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHMS; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG DOSAGE CALCULATIONS; HUMANS; MORPHOLINES; PHARMACOGENETICS; PYRAZOLES; PYRIDONES; QUALITY-ADJUSTED LIFE YEARS; STROKE; THIOPHENES; WARFARIN;

EID: 84893797996     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.190     Document Type: Article

References (39)

1. Connolly, S.J. et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361, 1139-1151 (2009).
2. Patel, M.R. et al.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365, 883-891 (2011).
3. Granger, C.B. et al.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365, 981-992 (2011).
4. Matchar, D.B. et al.; THINRS Executive Committee and Site Investigators. Effect of home testing of international normalized ratio on clinical events. N. Engl. J. Med. 363, 1608-1620 (2010).
5. You, J.H., Tsui, K.K., Wong, R.S. & Cheng, G. Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy. Clin. Pharmacol. Ther. 86, 540-547 (2009).
6. Johnson, J.A. et al.; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin. Pharmacol. Ther. 90, 625-629 (2011).
7. Jorgensen, A.L., FitzGerald, R.J., Oyee, J., Pirmohamed, M. & Williamson, P.R. Influence of CYP2C9 and VKORC1 on patient response to warfarin: A systematic review and meta-analysis. PLoS ONE 7, e44064 (2012).
8. Wadelius, M. et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113, 784-792 (2009).
9. McKeage, K. Dabigatran etexilate: A pharmacoeconomic review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Pharmacoeconomics 30, 841-855 (2012).
10. Limdi, N.A. & Veenstra, D.L. Warfarin pharmacogenetics. Pharmacotherapy 28, 1084-1097 (2008).
11. Salinger, D.H., Shen, D.D., Thummel, K., Wittkowsky, A.K., Vicini, P. & Veenstra, D.L. Pharmacogenomic trial design: Use of a PK/PD model to explore warfarin dosing interventions through clinical trial simulation. Pharmacogenet. Genomics 19, 965-971 (2009).
12. Hughes, D.A. & Walley, T. Economic evaluations during early (phase II) drug development: A role for clinical trial simulations Pharmacoeconomics 19, 1069-1077 (2001).
13. Anderson, J.L. et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation 125, 1997-2005 (2012).
14. International Warfarin Pharmacogenetics Consortium; Klein, T.E. et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360, 753-764 (2009).
15. Reynolds, M.W. et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: A systematic review and metaanalysis. Chest 126, 1938-1945 (2004).
16. Pink, J., Lane, S., Pirmohamed, M. & Hughes, D.A. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: Quantitative benefit-harm and economic analyses. BMJ 343, d6333 (2011).
17. Hughes, D.A. & Pirmohamed, M. Warfarin pharmacogenetics: Economic considerations. Pharmacoeconomics 25, 899-902 (2007).
18. Patrick, A.R., Avorn, J. & Choudhry, N.K. Cost-effectiveness of genotypeguided warfarin dosing for patients with atrial fibrillation. Circ. Cardiovasc. Qual. Outcomes 2, 429-436 (2009).
19. Eckman, M.H., Rosand, J., Greenberg, S.M. & Gage, B.F. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann. Intern. Med. 150, 73-83 (2009).
20. Meckley, L.M., Gudgeon, J.M., Anderson, J.L., Williams, M.S. & Veenstra, D.L. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics 28, 61-74 (2010).
21. You, J.H., Tsui, K.K., Wong, R.S. & Cheng, G. Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation. PLoS ONE 7, e39640 (2012).
22. Joo, J., Geller, N.L., French, B., Kimmel, S.E., Rosenberg, Y. & Ellenberg, J.H. Prospective alpha allocation in the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Clin. Trials 7, 597-604 (2010).
23. US National Institute of Health. Warfarin adverse event reduction for adults receiving genetics testing at therapy initiation (WARFARIN) trial. (2011).
24. Caro, J.J., Moller, J.& Getsios, D. Discrete event simulation: The preferred technique for health economic evaluations Value Health 13, 1056-1060 (2010).
25. O'Dell, K.M., Igawa, D. & Hsin, J. New oral anticoagulants for atrial fibrillation: A review of clinical trials. Clin. Ther. 34, 894-901 (2012).
26. Drummond, M.F., Sculpher, M.J., Torrance, G.W., O'Brien, B. & Stoddart, G.L. Methods for the Economic Evaluation of Health Care Programmes (Oxford University Press, Oxford, UK, 2005).
27. Hamberg, A.K. et al. A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age. Clin. Pharmacol. Ther. 87, 727-734 (2010).
28. van Schie, R.M. et al. Genotype-guided dosing of coumarin derivatives: The European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 10, 1687-1695 (2009).
29. Rosendaal, F.R., Cannegieter, S.C., van der Meer, F.J. & Briet, E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb. Haemost. 69, 236-239 (1993).
30. Baglin, T.P., Keeling, D.M. & Watson, H.G.; British Committee for Standards in Haematology. Guidelines on oral anticoagulation (warfarin): Third edition-2005 update. Br. J. Haematol. 132, 277-285 (2006).
31. Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M. & Palareti, G.; American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133, 160S-198S (2008).
32. Platt, A.B. et al. Risk factors for nonadherence to warfarin: Results from the INRANGE study. Pharmacoepidemiol. Drug Saf. 17, 853-860 (2008).
33. Gallagher, A.M., Rietbrock, S., Plumb, J. & van Staa, T.P. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: Do the appropriate patients receive stroke prophylaxis J. Thromb. Haemost. 6, 1500-1506 (2008).
34. Pink, J., Pirmohamed, M. & Hughes, D.A. Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation. Clin. Pharmacol. Ther. 94, 269-276 (2013).
35. Lenzini, P. et al. Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin. Pharmacol. Ther. 87, 572-578 (2010).
36. Department of Health. NHS reference costs 2010/11. London, Department of Health (2009).
37. Joint Formulary Committee of the British Medical Association and the Royal Pharmaceutical Society. British National Formulary 59th edn. (BMJ Group, Royal Pharmaceutical Society, London, 2010).
38. National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal (National Institute for Health and Care Excellence, London, 2013).
39. Fenwick, E., Claxton, K. & Sculpher, M. Representing uncertainty: The role of cost-effectiveness acceptability curves. Health Econ. 10, 779-787 (2001).